Trial Profile
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Mar 2023
Price :
$35
*
At a glance
- Drugs Mirikizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms OASIS-3
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 09 Feb 2023 This trial has been discontinued in Czechia (End date: 7 Feb 2022) as per European Clinical Trials Database record.
- 19 Jan 2023 Status changed from completed to discontinued.
- 11 May 2022 This trial has been discontinued in Poland (End date: 27 April 2021) as per European Clinical Trials Database record.